TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03384069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Cognitive Behavioral Therapy (CBT)
Description: The group-based CBT intervention will include twelve 1-hour group sessions held biweekly for six months. Each sixty-minute session will consist of 15 minutes of Alzheimer's disease (AD) prevention education and approximately 45 minutes of CBT presentations/engagement activities. A physician and a Behavioral Interventionist will collaboratively facilitate the group sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-based Cognitive Behavioral Therapy (CBT)
Description: Participants in the phone-based CBT will be asked to reserve a 1-hour period for a phone call from the Behavioral Interventionist biweekly for six months. Text reminders will be sent to the participant's prior the sessions. This intervention will follow the same frequency and format as the group-based CBT and will use an established protocol incorporating the same elements of cognitive behavior change as in the group-based CBT, but without the opportunity for group-interaction.
Study: NCT04426045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block
Description: A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.2% will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra-inguinal fascia iliaca compartment block
Description: A linear 6-13-MHz ultrasound probe will be placed in the sagittal plane to obtain an image of the anterior superior iliac spine. The fascia iliaca and sartorius, iliopsoas, and oblique internal muscles will be identified by sliding the probe medially. After identifying the bow-tie sign formed by the muscle fascias, a 22-gauge, 80-mm needle will be introduced 1 cm cephalad to the inguinal ligament. Using an in-plane approach, the fascia iliaca will be penetrated and hydrodissected, separating the fascia iliaca from the iliac muscle. A total volume of 30 ml of ropivacaine 0.2% will be injected.
Study: NCT06153641

Intervention type: OTHER
Intervention: N/A-Observational Study
Description: N/A-Observational Study
Study: NCT00369824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Different formulations of GSK Biologicals' HPV vaccine (580299)
Description: Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra TM
Description: One dose of vaccine administered intramuscularly
Study: NCT06153641

Intervention type: OTHER
Intervention: N/A-Observational Study
Description: N/A-Observational Study

Intervention type: OTHER
Intervention: N/A-Observational Study
Description: N/A-Observational Study
Study: NCT01641913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absorbable sugars
Description: Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
Study: NCT03083119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuesaitong soft capsule
Description: Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
Study: NCT05105646

Intervention type: PROCEDURE
Intervention: Knee Arthroplasty, knee revision arthoplasty
Description: Primary knee arthroplasty (e.g., total, unicondylar and patellofemoral)
Study: NCT03776890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DeStress for Health Program
Description: The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
Study: NCT01714882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management & Resiliency Training
Description: The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management DVD
Description: The couples in this group will receive a Mayo Clinic Stress Management DVD.
Study: NCT01970618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1162 single dose
Description: Safety and tolerability of single escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1162 matching placebo single dose
Description: Safety and tolerability of single escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1162: 7 day repeat dose
Description: Safety and tolerability of a repeat dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1162 matching placebo: 7 day repeat dose
Description: Safety and tolerability of a repeat dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1162: 14 day repeat dose
Description: Safety and tolerability of repeat escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1162 matching placebo: 14 day repeat dose
Description: Safety and tolerability of repeat escalating doses
Study: NCT03034681

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy technique: TENS

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy technique: Vojta Therapy
Study: NCT00442117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate dry powder inhaler
Description: MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks.
Study: NCT01908621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF (filgrastim)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytosine arabinoside + G-CSF (filgrastim)
Study: NCT03021434

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community and household water safety education sessions
Description: Data collectors will give a short community presentation on water treatment, as well as safe water handling and storage. Then, data collectors will immediately visit households and review this information. Data collectors will return within 72 hours and review this information once more.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community and household water safety education sessions
Description: Data collectors will give a short community presentation on water treatment, as well as safe water handling and storage. Then, data collectors will immediately visit households and review this information. Data collectors will return within 72 hours and review this information once more.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community and household water safety education sessions
Description: Data collectors will give a short community presentation on water treatment, as well as safe water handling and storage. Then, data collectors will immediately visit households and review this information. Data collectors will return within 72 hours and review this information once more.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Household-specific water quality information
Description: Household specific water quality data will be provided in two ways. In the Standard Testing Arm, water quality data will be analyzed in a laboratory by standard methods and results will be delivered to households. In the Test Kit arm, water quality data will be analyzed in households using provided water test kits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Household-specific water quality information
Description: Household specific water quality data will be provided in two ways. In the Standard Testing Arm, water quality data will be analyzed in a laboratory by standard methods and results will be delivered to households. In the Test Kit arm, water quality data will be analyzed in households using provided water test kits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-cost microbiological water test kits
Description: Intervention component consists of low-cost, biodegradable that tests for the presence of E. coli in water samples. The test uses Aquatest broth medium with resorufin methyl ester chromogen. Presence of E. coli (positive test) imparts bright red color, making it easy to use/interpret at the household level with minimal training
Study: NCT01672021

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET/MRI
Description: PET/MRI
Study: NCT00649376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine Tablets 180 mg
Description: 180mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allegra® Tablets 180 mg
Description: 180mg, single dose fasting
Study: NCT02211976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeticone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeticone
Study: NCT01371487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Oral/once-daily single doses on Day 1 of Periods 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Oral/once-daily single doses on Day 1 of Periods 1 and 2
Study: NCT01554839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family of Heroes
Description: One hour online educational tool

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Baseline and Follow up Surveys
Description: Baseline and follow up questionaires completed online
Study: NCT00369824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra TM
Description: One dose of vaccine administered intramuscularly
Study: NCT03081104

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hystroscopy
Description: The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control.
Study: NCT01554839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline and Follow up Surveys
Description: Baseline and follow up questionaires completed online
Study: NCT01768598

Intervention type: OTHER
Intervention: Fracture - Boys
Description: Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years

Intervention type: OTHER
Intervention: Fracture - Girls
Description: Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years

Intervention type: OTHER
Intervention: Non Fracture - Boys
Description: Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years

Intervention type: OTHER
Intervention: Non Fracture - Girls
Description: Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
Study: NCT04282226

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active transcutaneous Vagal Nerve Stimulation (tVNS)
Description: The tVNS device will be attached to the left aspect of the neck to stimulate the cervical branch of the vagal nerve and connected to an MR safe electrical stimulator.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham transcutaneous Vagal Nerve Stimulation (tVNS)
Description: The tVNS device will be attached to anatomically distinct from the cervical branch of the vagal nerve.
Study: NCT04586868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An intervention development study
Description: Assessing the acceptability for a virtual reality intervention among adolescents with psychosis
Study: NCT03081104

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration
Description: The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration
Description: The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used.
Study: NCT03682965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-lymphatic allergenic extract
Description: Mountain Cedar pollen allergenic extract is an FDA-approved, commercially available product for diagnosis and hypo-sensitization treatment of allergies. The labeled use is deep subcutaneous or percutaneous injection. Hyposensitization treatment is typically a series of 30 - 70 injections over 3 - 5 years into the upper aspect of the arm. This investigation is a proof-of-concept study to evaluate an alternative hyposensitization regimen of 3 injections directly into an inguinal lymph node.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intra-lymphatic placebo
Description: The control group will receive a regimen of 3 injections of diluent (placebo) directly into an inguinal lymph node on the same schedule as the active treatment group.
Study: NCT04586868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A randomized feasibility study
Description: Feasibility of virtual reality environment for adolescents with psychosis
Study: NCT00442117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide DPI
Description: Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks.
Study: NCT02140138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV9104
Study: NCT04586868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A single-case study
Description: The clinical efficacy of a novel VR-assisted CBT interventions for adolescents with psychosis
Study: NCT02357849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: see arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: see arm description
Study: NCT03214692

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Description: Oral intake of GA in powder from30 grams per day
Study: NCT01155297

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: The exercise program will be held three times a week and will have three stages: local and global stretching, aerobic exercise for 30 minutes ( with 50 and 60% of maximal heart rate) and strength training. The strength training will be done after assessment of one repetition maximum (1RM) and the prescription will be made with 50% load of 1RM, where the patient will hold three sets of 10-12 repetitions. Reassessments will be conducted monthly for readjustment of the charges. The duration of the training protocol will be six months.~After completing this exercise program, patients will undergo a reassessment repeating the ET and reapplication of the SF-36, redone the collection of ADMA serum concentration.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stretching and metabolic exercises
Description: At the control group will be performed stretching and metabolic exercises and will make the assessments and the reassessments after the end of the program.
Study: NCT00472472

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel coated balloon catheter (device with drug)
Description: PTA vs Paccocath

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel coated balloon catheter (device with drug)
Description: PTA vs Paccocath
Study: NCT03201146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Doses to be determined following the completion of Phase I of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AP or AC
Description: Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP or AC
Description: Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP or AC
Description: Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP or AC
Description: Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP or AC
Description: Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib 250mg
Description: 250mg/d,q.d.,p.o.every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib 500mg
Description: 500mg/d,q.d.,p.o.every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib 750mg
Description: 750mg/d,q.d.,p.o.every 21 days.
Study: NCT01368393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Patients randomized to the experimental group will receive electroacupuncture at acupoints relevant to the treatment of abdominal pain and anxiety, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), and Neiguan (pericardium meridian PC-6). Electric stimulation will be employed to the needles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham acupuncture
Description: Sterile blunt-tip needles will be placed (without skin penetration) 15 mm away from the acupoints. Pseudostimulation will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current.
Study: NCT03157973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education intervention
Description: eHealth tool and standardized nurse-led follow-up.
Study: NCT00297362

Intervention type: DRUG
Intervention: Galantamine hydrobromide
Description: 247 patients with diagnosed mild to moderate Alzheimer disease.
Study: NCT03025334

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-definition transcranial direct current stimulation
Description: brain stimulation to increase neuronal excitability in the targeted regions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High-definition transcranial direct current stimulation
Description: brain stimulation to increase neuronal excitability in the targeted regions
Study: NCT03984331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fish skin
Description: One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cadaver skin
Description: One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
Study: NCT03378154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orotracheal intubation in infants with Macintosh
Description: Orotracheal intubation in infants using Macintosh laryngoscope

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orotracheal intubation in infants with King vision
Description: Orotracheal intubation in infants with King vision videolaryngoscope
Study: NCT03496467

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac PPDS
Description: A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that contains nepafenac, a nonsteroidal anti-inflammatory drug.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PPDS
Description: A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that does not contain nepafenac.
Study: NCT01626352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Patients will receive as an IV infusion bendamustine 90 mg/m\^2 Days 1 and 2 of Cycles 1 through 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Patients will receive as an IV infusion ofatumumab 1000-mg IV Days 1 and 8 during Cycle 1 only, and on Day 1 of Cycles 2 through 6